Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of linsitinib compound in preparation of anti-ev71 virus medicine

A compound and virus technology, applied in antiviral agents, pharmaceutical formulations, medical preparations containing active ingredients, etc., to achieve great clinical application prospects, reduce production, and inhibit cytopathic effects

Active Publication Date: 2022-01-04
HUBEI UNIV OF TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, OSI-906 is rarely reported for antiviral therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of linsitinib compound in preparation of anti-ev71 virus medicine
  • Application of linsitinib compound in preparation of anti-ev71 virus medicine
  • Application of linsitinib compound in preparation of anti-ev71 virus medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The present invention has carried out anti-EV71 activity research experiments on the above-mentioned compounds, and the experimental conditions are as follows: In the following, if not specified, the materials and operation methods used in the present invention are well known in the art.

[0022] 1. Test content:

[0023] Anti-EV71 activity analysis of compounds: In this invention, the anti-EV71 activity of OSI-906 will be evaluated by combining cytopathic effect analysis and MTT assay cell survival rate detection method.

[0024] 2. Test method:

[0025] 2.1.1 Toxicity of compounds to host RD cells

[0026] Plate RD cells into 96-well plates at 37 °C, 5% CO 2 After the monolayer was grown in the incubator, the cell culture solution was discarded, and the cell maintenance solution containing different concentrations of the test compound was added to continue the culture. After 48 hours, the cytotoxicity was visually observed under the microscope and recorded respectiv...

Embodiment 2

[0038] The present invention has carried out an in-depth study on the anti-EV71 activity of OSI-906, and implemented the inhibitory effect test of the compound on the production of EV71 progeny virus. The test conditions are as follows:

[0039] 1. Test content

[0040] After EV71 infected RD cells, the inhibitory effect of the compound on the production of EV71 progeny virus was detected.

[0041] 2. Test method

[0042] RD cells in the logarithmic growth phase were plated in 24-well plates, and 100TCID after the monolayer was overgrown 50 EV71 infected cells, incubated at 37°C for 1.5h, removed the virus solution, washed three times with PBS, and added cell maintenance solution containing 25μM concentration. After 48 hours, the cells and supernatant were collected and lysed by freezing and thawing three times at -20°C and 37°C. TCID 50 Methods The titer of EV71 virus was determined.

[0043] 3. Test results

[0044] Such as image 3 As shown, compared with the virus c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of a Linsitinib compound in the preparation of anti-EV71 virus medicine. Through the research experiment on the anti-EV71 activity of Linsitinib, the compound Linsitinib inhibits the cytopathic effect (CPE) produced by EV71 on the host cell RD, enhances the cell survival rate, reduces the progeny virus production, and can be used in the preparation of anti-EV71 virus drugs.

Description

technical field [0001] The invention relates to the technical field of antiviral drugs, in particular to the application of a Linsitinib compound in the preparation of anti-EV71 virus drugs. Background technique [0002] Enterovirus 71 (EV71) is a member of the genus Enterovirus in the Picornaviridae family, and is one of the most important pathogens causing hand, foot and mouth disease in infants, sometimes accompanied by severe central nervous system complications. Including aseptic meningitis, encephalitis, poliomyelitis-like paralysis, nervous cardiopulmonary failure, etc., and even death. In 2008, the Chinese government listed HFMD as a Class C infectious disease and brought it under management, and formulated a series of relevant laws and regulations to strictly control the spread of HFMD. At present, there is no specific drug for the treatment of diseases infected by EV71. The relevant vaccine was only launched in 2015, and its preventive effect remains to be further...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4985A61P31/14
CPCA61K31/4985A61P31/14
Inventor 魏艳红刘会会王海欣胡康洪李涵洛胡达杨娜史玥玡
Owner HUBEI UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com